These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30967632)

  • 81. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.
    Austin RJ; Straube J; Bruedigam C; Pali G; Jacquelin S; Vu T; Green J; Gräsel J; Lansink L; Cooper L; Lee SJ; Chen NT; Lee CW; Haque A; Heidel FH; D'Andrea R; Hill GR; Mullally A; Milsom MD; Bywater M; Lane SW
    Leukemia; 2020 Apr; 34(4):1075-1089. PubMed ID: 31732720
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
    Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The Hematopoietic Microenvironment in Myeloproliferative Neoplasms: The Interplay Between Nature (Stem Cells) and Nurture (the Niche).
    Zhan H; Kaushansky K
    Adv Exp Med Biol; 2020; 1273():135-145. PubMed ID: 33119879
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells.
    Tan G; Wolski WE; Kummer S; Hofstetter M; Theocharides APA; Manz MG; Aebersold R; Meier-Abt F
    Blood Adv; 2022 Jun; 6(11):3480-3493. PubMed ID: 35008095
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms.
    Tong J; Sun T; Ma S; Zhao Y; Ju M; Gao Y; Zhu P; Tan P; Fu R; Zhang A; Wang D; Wang D; Xiao Z; Zhou J; Yang R; Loughran SJ; Li J; Green AR; Bresnick EH; Wang D; Cheng T; Zhang L; Shi L
    Cell Stem Cell; 2021 Mar; 28(3):502-513.e6. PubMed ID: 33621485
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation.
    Jacquelin S; Straube J; Cooper L; Vu T; Song A; Bywater M; Baxter E; Heidecker M; Wackrow B; Porter A; Ling V; Green J; Austin R; Kazakoff S; Waddell N; Hesson LB; Pimanda JE; Stegelmann F; Bullinger L; Döhner K; Rampal RK; Heckl D; Hill GR; Lane SW
    Blood; 2018 Dec; 132(26):2707-2721. PubMed ID: 30366920
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome.
    Sozer S; Fiel MI; Schiano T; Xu M; Mascarenhas J; Hoffman R
    Blood; 2009 May; 113(21):5246-9. PubMed ID: 19293426
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
    Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW
    Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Prevalence of CYLD mutations in Vietnamese patients with polycythemia vera.
    Trang DT; Giang NH; Trang BK; Ngoc NT; Giang NV; Canh NX; Vuong NB; Xuan NT
    Adv Clin Exp Med; 2022 Apr; 31(4):369-380. PubMed ID: 35025147
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.
    Zheng Y; Qin H; Frank SJ; Deng L; Litchfield DW; Tefferi A; Pardanani A; Lin FT; Li J; Sha B; Benveniste EN
    Blood; 2011 Jul; 118(1):156-66. PubMed ID: 21527517
    [TBL] [Abstract][Full Text] [Related]  

  • 92. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2.
    Kagoya Y; Yoshimi A; Tsuruta-Kishino T; Arai S; Satoh T; Akira S; Kurokawa M
    Blood; 2014 Nov; 124(19):2996-3006. PubMed ID: 25217696
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Differential expression of hydroxyurea transporters in normal and polycythemia vera hematopoietic stem and progenitor cell subpopulations.
    Tan G; Meier-Abt F
    Exp Hematol; 2021 May; 97():47-56.e5. PubMed ID: 33677043
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Analysis of Jak2 signaling reveals resistance of mouse embryonic hematopoietic stem cells to myeloproliferative disease mutation.
    Mascarenhas MI; Bacon WA; Kapeni C; Fitch SR; Kimber G; Cheng SW; Li J; Green AR; Ottersbach K
    Blood; 2016 May; 127(19):2298-309. PubMed ID: 26864339
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches.
    Pearson S; Williamson AJK; Blance R; Somervaille TCP; Taylor S; Azadbakht N; Whetton AD; Pierce A
    Leukemia; 2017 Dec; 31(12):2717-2725. PubMed ID: 28533538
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Frequency of Zygosity in Jak-2 Positive Patients with Polycythemia Vera-Pakistan's Perspective.
    Shah SZ; Raza N; Nasir MI; Zaidi SMH
    Asian Pac J Cancer Prev; 2021 Feb; 22(2):559-564. PubMed ID: 33639674
    [TBL] [Abstract][Full Text] [Related]  

  • 97. CRISPR/Cas9 mediated CXCL4 knockout in human iPS cells of polycythemia vera patient with JAK2 V617F mutation.
    Boehnke J; Atakhanov S; Toledo MAS; Schüler HM; Sontag S; Chatain N; Koschmieder S; Brümmendorf TH; Kramann R; Zenke M
    Stem Cell Res; 2021 Aug; 55():102490. PubMed ID: 34391098
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera.
    Lanikova L; Babosova O; Swierczek S; Wang L; Wheeler DA; Divoky V; Korinek V; Prchal JT
    Blood; 2016 Nov; 128(18):2266-2270. PubMed ID: 27647865
    [No Abstract]   [Full Text] [Related]  

  • 99. Distinct profile of CD34
    Forte D; Barone M; Morsiani C; Simonetti G; Fabbri F; Bruno S; Bandini E; Sollazzo D; Collura S; Deregibus MC; Auteri G; Ottaviani E; Vianelli N; Camussi G; Franceschi C; Capri M; Palandri F; Cavo M; Catani L
    J Exp Clin Cancer Res; 2021 Feb; 40(1):49. PubMed ID: 33522952
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The ERK2-DBP domain opposes pathogenesis of a mouse JAK2V617F-driven myeloproliferative neoplasm.
    Zhang Y; Truong B; Fahl SP; Martinez E; Cai KQ; Al-Saleem ED; Gong Y; Liebermann DA; Soboloff J; Dunbrack R; Levine RL; Fletcher S; Kappes D; Sykes SM; Shapiro P; Wiest DL
    Blood; 2022 Jul; 140(4):359-373. PubMed ID: 35436326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.